Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Parkinson's disease psychosis
ISRCTN87895237Phase 2Completed
- Sponsor
- King's College London
- Start
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Parkinson's disease (PD), sponsored by King's College London. Primary endpoints: Maximum tolerated dose of cannabidiol and Safety and tolerability. Started Oct 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN87895237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87895237.